Immunovia's Warrant Exercise Period Begins: A Path to US Market Expansion and Clinical Studies

Immunovia AB (IMMNOV: Nasdaq Stockholm) has announced that the exercise period for warrants of series TO 2 begins today, January 2, 2025. This marks an important milestone for the pancreatic cancer diagnostics company, as it seeks to fund key initiatives and drive growth. The warrant exercise period will run up to and including January 16, 2025, with the last day for trading in the warrants being January 14, 2025.

The subscription price for the warrants has been set at SEK 0.46, which is 70 percent of the volume-weighted average price for the Company's share on Nasdaq Stockholm during the period 12 - 27 December 2024. This price is within the allowed range, not exceeding an amount corresponding to 125 percent of the subscription price per share in the Rights Issue (SEK 0.63). The subscription price is set at the lower end of the allowed range, which may make the warrants more attractive to investors.

Immunovia has received subscription intentions from its CEO and board members, totaling approximately SEK 0.8 million, which corresponds to approximately 1.3 percent of the Warrant Programme. Additionally, the company has received subscription commitments and guarantee commitments from external professional investors, amounting to approximately SEK 0.1 million and SEK 36.3 million, respectively. These commitments correspond to approximately 0.3 percent and 63.4 percent of the Warrant Programme, respectively. As such, the warrant programme is secured to approximately SEK 37.2 million, corresponding to approximately 65.0 percent of the warrant programme.

The proceeds from the exercise of the TO2 warrants will fund preparations to introduce Immunovia's next-generation test to the US market in the second half of 2025. This capital will also support clinical studies to bolster the company's efforts to obtain reimbursement for the test. The US market is the world's largest market for detection of pancreatic cancer, with an estimated 1.8 million individuals at high-risk for the disease. Expanding into this market represents a significant opportunity for Immunovia to increase its revenue and market share.



Immunovia's CEO, Jeff Borcherding, has expressed confidence in the company's mission and the potential of its next-generation test. He believes that the recently announced CLARITI study results validate the accuracy of the test and prove that Immunovia has the right test to meet the unmet need for an accurate blood test to detect pancreatic cancer early in high-risk individuals. With the proceeds from the warrant exercise, Immunovia will be well-positioned to achieve its key milestones and drive the commercial success of its test.

In conclusion, the exercise period for Immunovia's warrants of series TO 2 represents an important opportunity for the company to secure funding for its US market expansion and clinical studies. With a subscription price set at the lower end of the allowed range and strong support from the company's CEO and board members, as well as external professional investors, Immunovia is well-positioned to achieve its growth objectives. As the warrant exercise period begins, investors should closely monitor Immunovia's progress and consider the potential impact on the company's share price and market capitalization.